Previous 10 | Next 10 |
With the advent of a series of successful vaccines, global markets can almost afford to be oblivious to virus headlines and instead focus on the medium term when economies have reopened. But, against this backdrop, a big question for investors must be: how quickly can populations be vacci...
BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private investments. These companies are ripe for significant growth, at the same time, BM...
BSTZ was the top-performing closed-end fund in 2020. Chances are 2021 might not be so spectacular, but that doesn't mean strong returns can't be achieved again. As we entered into 2021, pressure mounted against tech and sent shares of BSTZ on a dip. Magnifying this is the widening...
The Liberty All-Star Growth fund has got to be the greatest trading fund among all-equity CEFs. This will be the third time in just the last few months that you could have bought ASG at essentially par valuation and sold within two to three weeks at a roughly 12% premium. That's w...
Readers have shown interest in seeing some of my top holdings outside of my closed-end portfolio. I hold a total of 30 stocks in this portfolio that all have a track record of dividend growth over the years. This portfolio is smaller, and less focused on overall diversification - ...
Though I'm not nearly as optimistic about 2021 as most prognosticators, we still have to go through the ritual of giving our Top Picks for the year. Looking back over 2020, it really was a year for huge winners and huge losers. There really was not a tide lifting all boats until...
Some readers had showed interest in hearing what my personal top ten positions are. Using Portfolio Visualizer's tools looking through my top ten can provide some interesting data. These names should all be familiar, as a lot are held in the CEF/ETF Income Laboratory model portfol...
It is important to remember that not all return of capital is necessarily destructive to a fund. Return of capital is a tax term and not a term for evaluating performance. Some investors look for return of capital to defer tax obligations, potentially indefinitely. For furth...
As the year is starting to wind down, I wanted to take an updated look at what distribution changes happened throughout the year. We had previously done this for a more specific time frame; the time frame of the pandemic to shortly after in June. Again, I'm surprised at how resili...
The Columbia Seligman Premium Technology Growth Fund is a quality closed-ended fund with an attractive dividend yield of 7.26%. However, its stellar performance has been outclassed by another closed-ended technology fund, the BlackRock Science and Technology Trust. Everything cons...
News, Short Squeeze, Breakout and More Instantly...
BlackRock Science and Technology Trust of Beneficial Interest Company Name:
BST Stock Symbol:
NYSE Market:
BlackRock Science and Technology Trust of Beneficial Interest Website:
BlackRock Advisors, LLC released today share repurchase activity for certain BlackRock closed-end funds (the “Funds”) during the quarter ended June 30, 2022. The Funds have authorized open market share repurchase programs (the “Repurchase Programs”) pursuant ...
Today I want to show you how to build a “three-click” income portfolio that gives us three things every income investor craves, especially these days: Big discounts on our investments. Big dividends, with a 10.6% yield averaged out across three funds. Wide di...
With 2022 likely to be a wild ride, we income investors are going to lean on two key advantages. In doing so, we’ll secure 7% dividends no matter what the broader markets do. First, we can secure this “head start” by January 1 by purchasing funds that yield 7%, on a...